The aim of this study was to analyze the TNM classification factors of invasive breast cancer that can be affected by the national program for early detection of breast cancer in the Republic of Croatia. The other analyzed factors related to histology and immunohistochemistry have no such impact as they are related to biological behavior and aggressiveness of malignant breast tumors, thus providing useful predictive and prognostic information. The study was performed at Department of Oncologic Surgery, Sestre milosrdnice University Hospital Center, and included 75 patients surgically treated for invasive breast cancer during the period of one month in 2011, mean age 64 +/- 11.36 (range 36-86) years. Most of the patients (68%) with malignant breast disease were diagnosed in a localized stage, which is consistent with the reports from developed European countries. The size of the newly discovered tumors showed continuation of a trend of detecting tumors of ever less size and a lower percentage of pT3 pT4 tumors. This result proved superior to those reported from many European countries. The results of correlation analysis, tumor size, estrogen and progesterone receptor, HER-2 protein, Ki-67, and histologic tumor grade, tumor size did not show significant correlation with any of these parameters. Concordant expression of phenotype (ER+, PR+) receptor pairs and negative HER-2 was recorded in most study patients. The second most frequent group had tumors with so-called 'triple-negative' immunohistochemistry negative phenotype (ER-, PR-, HER-2). In conclusion, the program of early detection of breast cancer in the Republic of Croatia and at the University Hospital for Tumors justifies its existence for revealing malignant breast tumors at an earlier stage of the disease considering the size local stage of newly diagnosed tumors.
Download full-text PDF |
Source |
---|
Sleep
January 2025
Department of Psychology, Faculty of Science, Memorial University, St. John's, NL, Canada.
Study Objectives: Cancer-related fatigue is one of the most common symptoms in cancer survivors. Cognitive behavioural therapy for insomnia (CBT-I) can improve fatigue, but mechanisms are unclear. This secondary analysis of a randomized controlled trial evaluated whether CBT-I led to a significant improvement in fatigue, accounting for change in comorbid symptoms of insomnia, perceived cognitive impairment (PCI), anxiety, and depression.
View Article and Find Full Text PDFPhotochem Photobiol Sci
January 2025
Homi Bhabha National Institute, Training School Complex, Anushaktinagar, Mumbai, 400094, India.
The efficacy of photodynamic treatment (PDT) against deep-seated tumor is hindered by low penetration depth of light as well as hypoxic conditions which prevails in tumor. To overcome this limitation, Near-infrared (NIR) absorbing photosensitizers have been investigated actively. In the present study we evaluated the PDT efficacy of an NIR absorbing chlorophyll derivative 'Cycloimide Purpurin-18 (CIPp-18)' in Human Breast carcinoma (MCF-7) and cervical adenocarcinoma (Hela) cells under normoxic and hypoxic conditions.
View Article and Find Full Text PDFCurr Oncol Rep
January 2025
Radiation Oncology Department, General Regional Hospital "F.Miulli", Acquaviva Delle Fonti, Bari, Italy.
Purpose Of Review: Male breast cancer (MBC) is a rare entity which often arises in elderly people. Aim of this review is to evaluate the principal issues related to MBC in elderly, because the therapeutic management of disease is not only related to the biological behavior of the tumor, but also to the comorbidities and frailty of older population. A scoping literature review was performed on Pubmed and Cochrane Database using the following keywords: therapeutic management/ male/ breast cancer/ elderly patients.
View Article and Find Full Text PDFCancer Commun (Lond)
January 2025
Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, P. R. China.
Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.
Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.
Womens Health (Lond)
January 2025
Research Centre for Public Health, Equity and Human Flourishing, Torrens University Australia, Adelaide, SA, Australia.
Background: Population-level mammography screening for early detection of breast cancer is a secondary prevention measure well-embedded in developed countries, and the implications for women's health are widely researched. From a public health perspective, efforts have focused on why mammography screening rates remain below the 70% screening rate required for effective population-level screening. From a sociological perspective, debates centre on whether 'informed choice' regarding screening exists for all women and the overemphasis on screening benefits, at the cost of not highlighting the potential harms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!